Profound Medical reported a gross margin of 78.41% and a net margin of -384.21% for the quarter ended Jun 2026. These financial ratios cover 17 quarters of results from Dec 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2018 | Jan2019 | Dec2019 | Dec2020 | Dec2021 | Dec2022 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||
| Gross Margin | 60.18% | 63.64% | 63.14% | 70.93% | 70.70% | 73.18% | 74.32% | 66.77% | 71.80% | 78.41% | |||||||
| EBT Margin | -454.83% | -309.00% | -324.44% | -135.37% | -407.59% | -706.97% | -148.53% | -153.94% | -131.68% | -382.00% | |||||||
| EBIT Margin | -547.39% | -351.19% | -317.73% | -199.83% | -426.02% | -624.42% | -168.52% | -123.29% | -150.29% | -445.67% | |||||||
| EBITDA Margin | -547.39% | -351.19% | -317.73% | -199.83% | -426.02% | -624.42% | -168.52% | -123.29% | -150.29% | -445.67% | |||||||
| Operating Margin | -547.39% | -351.19% | -317.73% | -199.83% | -426.02% | -624.42% | -168.52% | -123.29% | -150.29% | -445.67% | |||||||
| Net Margin | -457.61% | -309.85% | -330.69% | 1,213.72% | 409.16% | -709.86% | -150.82% | 1,287.69% | 132.15% | -384.21% | |||||||
| FCF Margin | -314.73% | -278.50% | -241.03% | -140.78% | -316.02% | -621.62% | -181.77% | -109.85% | -160.82% | -456.63% | |||||||
| Efficiency | |||||||||||||||||
| Inventory AverageInventory Avg. | 2.71M | 3.14M | 4.47M | 6.37M | 7.68M | 7.46M | 6.30M | 7.57M | 8.35M | 8.29M | 8.62M | 9.73M | |||||
| Assets AverageAssets Avg. | 34.70M | 31.85M | 67.09M | 95.69M | 75.60M | 54.19M | 65.55M | 55.27M | 45.99M | 59.89M | 75.47M | 67.92M | |||||
| Invested CapitalInvested Cap. | 29.23M | 28.28M | 23.13M | 60.29M | 40.43M | 66.82M | 55.28M | 43.72M | 41.10M | 70.93M | 68.43M | 58.82M | |||||
| Asset Utilization RatioAsset Util. | 0.18 | 0.21 | 0.31 | 0.27 | 0.25 | 0.28 | |||||||||||
| Leverage & Solvency | |||||||||||||||||
| Debt Ratio | 0.26 | 0.26 | 0.30 | 0.12 | 0.21 | 0.09 | 0.07 | 0.09 | 0.21 | 0.06 | 0.12 | 0.14 | |||||
| Valuation | |||||||||||||||||
| Price to EarningsP/E | -31.47 | -29.64 | -20.85 | 3.67 | 16.31 | -11.30 | -18.51 | 3.09 | 33.39 | -25.47 | |||||||
| Price to SalesP/S | 144.02 | 91.83 | 68.96 | 44.54 | 66.73 | 80.20 | 27.92 | 39.81 | 44.12 | 97.84 | |||||||
| Price to BookP/B | 9.18 | 4.27 | 2.89 | 4.32 | 5.81 | 4.55 | 5.27 | 6.36 | 3.08 | 3.44 | 4.52 | 4.59 | 3.58 | 3.96 | 4.88 | ||
| Enterprise Value | 115.23M | 331.58M | 166.16M | 180.86M | 155.22M | 207.24M | 205.06M | 195.30M | 131.08M | 128.48M | 142.12M | 122.82M | 178.21M | 185.17M | 204.67M | ||
| EV to EBIT | -26.31 | -26.15 | -21.70 | -15.71 | -11.51 | -10.29 | -13.78 | -24.18 | -23.09 | -18.50 | |||||||
| EV to EBITDA | -26.31 | -26.15 | -21.70 | -15.71 | -11.51 | -10.29 | -13.78 | -24.18 | -23.09 | -18.50 | |||||||
| Market Capitalization | 129.79M | 415.50M | 233.32M | 227.38M | 181.44M | 207.24M | 205.06M | 195.30M | 185.99M | 174.91M | 177.31M | 147.65M | 237.93M | 235.47M | 242.94M | ||
| Price to FCFP/FCF | -45.76 | -32.97 | -28.61 | -31.64 | -21.12 | -12.90 | -15.36 | -36.24 | -27.43 | -21.43 | |||||||
| EV to FCF | -45.76 | -32.97 | -28.61 | -22.30 | -15.51 | -10.34 | -12.78 | -27.14 | -21.57 | -18.05 | |||||||
| EV to CFO | -45.76 | -32.97 | -28.61 | -22.30 | -15.51 | -10.34 | -12.78 | -27.14 | -21.57 | -18.05 | |||||||
| Return Ratios | |||||||||||||||||
| Return on Sales [ROS]ROS | -547.39% | -351.19% | -317.73% | -199.83% | -426.02% | -624.42% | -168.52% | -123.29% | -150.29% | -445.67% | |||||||
| Return on Capital Employed [ROCE]ROCE | -60.33% | -85.41% | -117.15% | -76.66% | -58.76% | -60.14% | |||||||||||
| Return on Invested Capital [ROIC]ROIC | -51.88% | -76.94% | -89.15% | -62.89% | -45.95% | -45.06% | |||||||||||
| Return on Assets [ROA]ROA | -43.10% | -67.02% | -77.53% | -61.84% | -44.22% | -40.06% |